v3.26.1
License Revenues - Additional Information (Details) - USD ($)
3 Months Ended 6 Months Ended
Sep. 12, 2024
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2022
Dec. 31, 2025
Oct. 01, 2024
Sep. 11, 2023
Oct. 31, 2021
Sep. 30, 2020
Related Party Transaction [Line Items]                      
Common stock, Shares issued   54,798,338   54,798,338     43,223,090   11,021,248    
Reverse stock split       Immediately prior to the effective time of the Reverse Merger, the Company effected a 1-for-16 reverse stock split of its common stock (the “Reverse Stock Split”). Unless noted otherwise, all references herein to share and per share amounts reflect the Reverse Stock Split.              
Accounts receivable   $ 106,000   $ 106,000     $ 52,000        
Deferred revenue current   1,524,000   1,524,000     1,188,000        
Deferred revenue noncurrent   5,944,000   5,944,000     5,770,000        
Zenas BioPharma Inc [Member]                      
Related Party Transaction [Line Items]                      
Reimbursement of development costs           $ 1,100,000          
Common stock, Shares issued                     156,848
Zenas BioPharma Inc [Member] | IPO [Member]                      
Related Party Transaction [Line Items]                      
Price per share $ 17                    
Reverse stock split 1-for-8.6831                    
Fair value of the investment   500,000   500,000     700,000        
Zenas BioPharma Inc [Member] | Milestone [Member]                      
Related Party Transaction [Line Items]                      
Development milestones           11,000,000          
Zenas BioPharma Inc [Member] | Royalty [Member]                      
Related Party Transaction [Line Items]                      
License revenue - related party       0              
Zenas BioPharma Inc [Member] | Upfront Payment [Member]                      
Related Party Transaction [Line Items]                      
Upfront payments           $ 1,000,000       $ 1,000,000  
Tenacia Biotechnology (Hong Kong) Co., Limited [Member]                      
Related Party Transaction [Line Items]                      
License revenue - related party   800,000 $ 200,000 1,200,000 $ 1,400,000            
Accounts receivable   100,000   100,000     52,000        
Unbilled receivable   200,000   200,000     50,000        
Deferred revenue current   1,500,000   1,500,000     1,200,000        
Deferred revenue noncurrent   5,900,000   5,900,000     $ 5,800,000        
Tenacia Biotechnology (Hong Kong) Co., Limited [Member] | Milestone [Member]                      
Related Party Transaction [Line Items]                      
Development milestones   $ 15,000,000   15,000,000       $ 15,000,000      
Revenue related to milestones       $ 7,000,000              
Collaborative Arrangement, Revenue Not from Contract with Customer, Statement of Income or Comprehensive Income [Extensible Enumeration]       License revenue - related party              
Tenacia Biotechnology (Hong Kong) Co., Limited [Member] | Upfront Payment [Member]                      
Related Party Transaction [Line Items]                      
Upfront payments               $ 2,500,000